Clarifying differences in gene expression profile of umbilical cord vein and bone marrow-derived mesenchymal stem cells; a comparative in silico study
Informatics in Medicine Unlocked, ISSN: 2352-9148, Vol: 33, Page: 101072
2022
- 1Citations
- 9Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Mesenchymal stem cells (MSCs) represent a promising therapeutic approach due to their capacity for self-renewal, immunomodulatory properties, and tissue regenerative potential. The immunomodulatory properties of MSCs have opened up the use of these versatile cells for treating immune- and inflammation-mediated disease entities. In addition, MSCs have emerged as a perspective for anti-cancer therapy, showing a tendency to accumulate at tumor sites. In the present study, we analyzed two MSC types, human bone marrow-derived MSC (hBM-MSCs) and human umbilical cord-derived MSC (hUC-MSCs), with the same passage numbers and before their exposure to any stimulating environment to compare their immunomodulation and migration abilities. Various pro- and anti-inflammatory factors expressed by hBM-MSCs and hUC-MSCs in non-stimulating environments were screened out and compared. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) analysis were accomplished to determine functional annotation of the robust differentially expressed genes. Moreover, hub genes were identified using protein-protein interaction (PPI) network analysis. Our findings revealed that hUC-MSCs can express higher levels of pro- and anti-inflammatory factors compared to hBM-MSCs. Additionally, 1305 upregulated genes for hUC-MSCs and 1969 upregulated genes for hBM-MSCs were identified. We found that the limited number of hBM-MSCs upregulated genes were associated with some cancers and immune system diseases, yet the significant numbers of hUC-MSCs upregulated genes were mainly involved in pathways of neurodegeneration and cancers. Among all hub genes, estrogen receptor 1 (ESR1) and JUN achieved the highest scores in hBM-MSCs and hUC-MSCs, respectively. The novel data obtained from our study have declared the presence of a wide range of robust upregulated genes in hUC-MSCs, particularly JUN as a proto-oncogene, which can contribute to some life-threatening diseases.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2352914822002088; http://dx.doi.org/10.1016/j.imu.2022.101072; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85138568072&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2352914822002088; https://dx.doi.org/10.1016/j.imu.2022.101072
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know